Gut Microbes, 13 (1), 1907272
These structural refinements result in a half-life of approximately 160 h, enabling once-weekly subcutaneous administration while maintaining effective glycemic control (Fig
Liraglutide 3 mg (Saxenda, FDA-approved for weight management), an earlier-generation daily GLP-1 injection, demonstrates similar gastrointestinal side effect patterns with diarrhea reported in approximately 21% of patients according to its FDA label
GLP-1: molecular mechanisms and outcomes of a complex signaling system
Even if youre taking a GLP-1 medication, that may not be the only reason or even the main reason youre experiencing diarrhea
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
